The aim is not to discourage appropriate treatment, but to make sure warning symptoms are recognised early
Every person with type 1 diabetes should have the equipment to undertake BGM, regardless of whether they are using CGM
Firstly, considering the high tumor heterogeneity, various tumors or different regions within the same tumor can exhibit distinct metabolic profiles (Hensley et al., 2016)
for semaglutide (Wegovy), evaluate response once maintenance dose is reached Six-monthly reviews thereafter, including liver function tests, renal function, and metabolic parameters Annual comprehensive review including cardiovascular risk assessment NAFLD monitoring may include repeat FIB-4 or ELF testing
However, this means that the effects of treatment will be minimal until the target dose is reached and the titration period ends
estimated that pemvidutide could generate peak annual revenues of greater than $1 billion in metabolic dysfunction-associated steatohepatitis (MASH)